OBJECTIVES: To determine the efficacy and tolerability of bicalutamide in patients with advanced prostate cancer with progression after conventional hormonal therapy. METHODS: Fifty-two patients received bicalutamide, 150 mg once daily, as second-line therapy after progressing following treatment with orchiectomy or luteinizing hormone-releasing hormone analogue or diethylstilbestrol, alone or in combination. Patients had measurable (n = 8) orassessable (n = 44) disease, a Southwest Oncology Group performance status of 0 to 2, and no priorantiandrogen therapy or chemotherapy. The objective response to treatment was assessed every 12 weeks; symptoms and pain were assessed monthly with questionnaires for 6 months. RESULTS: There was evidence of palliation with three measures of pain and, to a lesser extent, with a measure of overall symptom status after 3 months of taking bicalutamide. No complete or partial responses occurred. However, 9 (20%) of 44 subjects with adequate prostate-specific antigen data had a 50% or higher decrease in their prostate-specific antigen levels, which did not correlate with symptom improvement. The median survival time was 15 months. The most common side effects were hot flashes (23%) and nausea (21%). CONCLUSIONS: These data suggest that bicalutamide decreases pain and improves symptom status in patients with prostate cancer in whom first-line hormonal therapy failed.
RCT Entities:
OBJECTIVES: To determine the efficacy and tolerability of bicalutamide in patients with advanced prostate cancer with progression after conventional hormonal therapy. METHODS: Fifty-two patients received bicalutamide, 150 mg once daily, as second-line therapy after progressing following treatment with orchiectomy or luteinizing hormone-releasing hormone analogue or diethylstilbestrol, alone or in combination. Patients had measurable (n = 8) or assessable (n = 44) disease, a Southwest Oncology Group performance status of 0 to 2, and no prior antiandrogen therapy or chemotherapy. The objective response to treatment was assessed every 12 weeks; symptoms and pain were assessed monthly with questionnaires for 6 months. RESULTS: There was evidence of palliation with three measures of pain and, to a lesser extent, with a measure of overall symptom status after 3 months of taking bicalutamide. No complete or partial responses occurred. However, 9 (20%) of 44 subjects with adequate prostate-specific antigen data had a 50% or higher decrease in their prostate-specific antigen levels, which did not correlate with symptom improvement. The median survival time was 15 months. The most common side effects were hot flashes (23%) and nausea (21%). CONCLUSIONS: These data suggest that bicalutamidedecreases pain and improves symptom status in patients with prostate cancer in whom first-line hormonal therapy failed.
Authors: José López Torrecilla; Asunción Hervás; Almudena Zapatero; Antonio Gómez Caamaño; Victor Macías; Ismael Herruzo; Xavier Maldonado; Alfonso Gómez Iturriaga; Francesc Casas; Carmen González San Segundo Journal: Rep Pract Oncol Radiother Date: 2015-05-30
Authors: Emma K Beardsley; Sebastien J Hotte; Scott North; Susan L Ellard; Eric Winquist; Christian Kollmannsberger; Som D Mukherjee; Kim N Chi Journal: Invest New Drugs Date: 2011-07-23 Impact factor: 3.850
Authors: Srikala S Sridhar; Anthony M Joshua; Richard Gregg; Christopher M Booth; Nevin Murray; Jovana Golubovic; Lisa Wang; Pamela Harris; Kim N Chi Journal: Clin Genitourin Cancer Date: 2014-06-08 Impact factor: 2.872